Salmeterol_Xinafoate: profile and news

[an error occurred while processing this directive]

Other information

Indication
For the treatment of Asthma and chronic obstructive pulmonary disease (COPD).

Pharmacology
Salmeterol, a highly selective beta(2)-agonist, is used to treat asthma and to prevent bronchospasm in patients with reversible obstructive airway disease.

Mechanism Of Action
Salmeterol's long, lipophilic side chain binds to exosites near beta(2)-receptors in the lungs and on bronchiolar smooth muscle, allowing the active portion of the molecule to remain at the receptor site, continually binding and releasing. Beta(2)-receptor stimulation in the lung causes relaxation of bronchial smooth muscle, bronchodilation, and increased bronchial airflow.

Drug Category
Bronchodilator Agents; Sympathomimetic; Adrenergic beta-Agonists;

Brand Names/Synonyms
Aeromax; Arial; Astmerole; CHEMBANK1801; SEREVENT; Salmetedur; Salmeterol; Salmeterol Xinafoate; Salmeterol [Usan:Ban:Inn]; Salmeterolum [Latin]; Serevent; [Usan:Ban:Inn]

Dosage Forms
METERED-DOSE (AEROSOL); POWDER

Absorption
Because of the small therapeutic dose, systemic levels of salmeterol are low or undetectable after inhalation of recommended doses (50 mcg of salmeterol inhalation powder twice daily). Following chronic administration of an inhaled dose of 50 mcg of salmeterol inhalation powder twice daily, salmeterol was detected in plasma within 5 to 45 minutes in 7 patients with asthma; plasma concentrations were very low, with mean peak concentrations of 167 pg/mL at 20 minutes and no accumulation with repeated doses.

Interactions